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and not yet fully understood. Phosphorus plays a major role, 
while other factors related to bone formation have been re-
cently identified.  Copyright © 2011 S. Karger AG, Basel 
 Vascular Calcification in Chronic Kidney Disease: 
Types and Risk Factors 
 In recent years, the main cause of morbidity and mor-
tality in chronic kidney disease (CKD) patients has been 
judged to be cardiovascular disease. Recent studies sug-
gest that vascular calcification plays a major role in car-
diovascular disease in dialysis patients. Following the 
recommendations of the Kidney Disease: Improving 
Global Outcomes Foundation  [1, 2] , kidney damage is de-
fined as structural or functional kidney abnormalities, 
which are accompanied by other abnormalities such as 
vascular calcification, bone loss and fractures, parathy-
roid dysfunction and several biochemical abnormalities, 
especially in serum PTH, calcium, phosphorus and alka-
line phosphatase. All together are today known as CKD 
bone and mineral disorders  [2] .
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 Abstract 
 Vascular calcification plays a major role in cardiovascular dis-
ease, which is one of the main causes of mortality in chronic 
kidney disease patients. Vascular calcification is determined 
by prevalent traditional and uraemia-related (non-tradition-
al) risk factors. It occurs mainly in the arteries, which are clas-
sified into three types according to their size and structural 
characteristics. In addition, vascular calcification has been 
associated with bone loss and fractures in chronic kidney 
disease patients and the general population, stressing the 
fact that both disorders can share pathogenetic pathways. 
The strategies to control vascular calcification involve sev-
eral measures, chief among them the control of hyperphos-
phataemia. Furthermore, it has been recently described that 
strategies that reduce bone resorption and increase bone 
mineralization may decrease the risk of vascular calcifica-
tions; however, this approach still remains controversial. The 
mechanisms involved in vascular calcification are complex 
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 The predisposition of patients with CKD towards de-
veloping vascular calcification was mentioned for the 
first time back in the 19th century; since then, many 
studies have addressed this important aspect. Vascular 
calcification occurs mainly in the arteries, which can be 
classified into three types according to their size and 
structure: elastic or large-calibre arteries, muscular or 
medium-calibre arteries and small-calibre arteries.
 Elastic or large-calibre arteries show a relatively thin 
wall in proportion to their diameter. The tunica media is 
rather thick and contains more elastic fibres than smooth 
muscle; the adventitia tends to be fairly thin. Through the 
elastic arteries, blood is conducted from the heart to the 
distribution arteries. Large vessels like the aorta, subcla-
via and common carotid arteries are included in this 
group.
 Muscular or medium-calibre arteries have a tunica 
media which contains a great proportion of smooth mus-
cle fibres; they are capable of withstanding further vaso-
dilatation and vasoconstriction to adjust the volume of 
blood to accommodate perfusion requirements. Medi-
um-calibre arteries include the axillary, brachial, radial, 
coronary, femoral and tibial arteries.
 Finally, small-calibre arteries are less than 2 mm thick 
and their tunica media contains only smooth muscle fi-
bres. In these vessels, luminal size variations, caused by 
vasoconstriction and vasodilatation of smooth muscle 
cells, are responsible for regulating the local blood flow 
and perfusion pressure. This group includes the palmar 
arch and the digital arteries, among others.
 The classical description of arterial calcification spec-
ifies it may occur in two locations: the intima and the 
media layers  [3] . Nevertheless, this classical concept is not 
fully accepted by all authors  [4, 5] .
 Intimal calcification begins and progresses under the 
influence of both genetic and lifestyle circumstances 
throughout a person’s lifetime. Intimal calcification is as-
sociated with a sequence of atherosclerotic events that in-
clude endothelial dysfunction, intimal edema, lipid cell 
formation and the migration of leukocytes and macro-
phages that can in turn cause a plaque rupture, thus lead-
ing to the formation of the thrombus  [6] . Atherosclerotic 
lesions have a patchy distribution along the length of the 
artery and may cause local stenoses and occlusions. Fur-
thermore, it is characterized by chronic arterial inflam-
mation exacerbated by alterations in lipid metabolism  [7] 
and other well-characterized risk factors, including hy-
pertension, diabetes, dyslipidemia  [8, 9] , obesity, smok-
ing and a family history of premature coronary heart dis-
ease.
 Calcification of the media occurs in the elastic lamina 
of large-calibre and medium- to small-size arteries; it 
seems to be independent of atherosclerosis, but both can 
coexist. This type of calcification was known initially as 
Monckeberg sclerosis and it can be seen radiographically 
as railroads  [10] . It typically affects arteries such as vis-
ceral abdominal, thyroid and lung  [10] , but it is also ex-
tremely common in the aorta, limb and femoral arteries. 
Calcification of the media increases linearly with age. It 
is frequently observed in patients with metabolic abnor-
malities such as hypervitaminosis D, CKD and diabetes 
 [11] .
 Table  1 summarizes the most prevalent traditional, 
uraemia-related and non-traditional risk factors for vas-
cular calcification in CKD patients. Like in the general 
population, traditional cardiovascular risk factors, pres-
ent in a large proportion of patients with CKD, are re-
sponsible to a great extent for the progression of vascular 
calcifications. Among non-traditional cardiovascular 
risk factors, including uraemia-related risk factors, hy-
perphosphatemia and the dialysis vintage are the risk fac-
tors more strongly associated with increased vascular cal-
cification and mortality  [12] . Elevated CRP and IL-6, as 
expression of chronic inflammation, have also been fre-
quently associated with vascular calcification.
Table 1.  Risk factors associated to vascular calcification in CKD 
patients
Traditional risk factors
Hypertension
Dyslipidaemia
Diabetes mellitus
Smoking
Older age
Family history of premature coronary heart disease
Uraemia-related and non-traditional risk factors
Time on dialysis
Hyperphosphatemia
High calcium-phosphorus product
Hyperparathyroidism and hypoparathyroidism
High dosage of vitamin D metabolites
Low fetuin-A
Anaemia
Poor nutrition (low albumin)
Chronic inflammation (CRP, IL-1, IL-6, TNF-)
Hyperhomocysteinaemia
Advanced glycated end-products
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 Clinical Impact of Vascular Calcification 
 As previously mentioned, CKD patients exhibit a very 
high percentage of vascular calcifications  [13–16] , leading 
to cardiovascular disease, decreased life expectancy and 
mortality  [17] even in the earliest phases of CKD. Russo 
et al.  [18] showed that 40% of patients with CKD (mean 
glomerular filtration rate 33 ml/min/1.73 m 2 ) suffered 
from calcification of the coronary arteries compared with 
13% of controls within a similar age range but with nor-
mal renal function. Kramer et al.  [19] found a significant 
positive association between the presence of coronary 
calcifications and renal failure, an association which in-
creased dramatically in CKD diabetic patients.
 CKD patients develop vascular calcification even at 
early ages  [16] and almost in all localizations in a greater 
proportion than the general population. They are fre-
quently localized in high-calibre arteries, such as the aor-
ta (79%), medium arteries (70.5%), including coronary 
arteries  [11] , and also in small calibre arteries (20.2%) 
 [20] . These differences may reflect the heterogeneity of 
the three categories of arteries studied, which also imply 
relevant functional changes in the vasculature  [21] . The 
calcification of the cardiac valves involves also a high risk 
of cardiovascular dysfunction  [22] in both general and 
haemodialysis (HD) populations.
 In a recent study, prevalent aortic calcifications were 
significantly higher in HD patients (79%) than in a ran-
dom-based general population of the same age, sex and 
region (37.5%)  [20] . Other reports have shown similar re-
sults in HD patients  [23] in which age was positively as-
sociated with vascular calcification in large and medium-
calibre arteries. Time on HD and total time on renal re-
placement therapy have been positively associated with 
vascular calcification, particularly in medium-calibre ar-
teries: each new year on renal replacement therapy in-
creased the risk of having vascular calcifications by ap-
proximately 15%  [24] . Therefore, the time spent on dialy-
sis is an important risk factor for medial and intimal 
arterial calcifications in CKD patients  [25] .
 In addition to information available for the HD pa-
tients, the Framingham study has shown that vascular 
calcification is also an independent predictor of vascular 
morbidity and mortality in the general population  [26] .
 Links between Vascular Calcification and Bone 
Disorders 
 Vascular calcification, bone loss and fragility fractures 
are very common disorders associated with aging, both 
in patients with CKD  [16, 27, 28] and in the general pop-
ulation  [29–32] . In recent years, several epidemiological 
studies have drawn attention to the relationship between 
vascular calcification and bone health  [31–34] . Even 
though the pathogenetic factors linking vascular calcifi-
cations and bone fragility are not fully understood, recent 
studies have shown that vascular calcification in some 
localizations were associated with an increased risk of 
fragility fractures in both general and HD populations 
 [20, 35, 36] .
 Strategies to Reduce Vascular Calcifications 
 Any strategy designed to reduce the impact of vascular 
calcifications has to begin with primary prevention mea-
sures to control cardiovascular risk factors. In the par-
ticular case of CKD, it is imperative to avoid further kid-
ney damage. In this respect, it is crucial to promote a 
healthy lifestyle, with a balanced diet, regular physical 
exercise, smoking abstinence and a low alcohol intake. 
Once vascular calcifications appear, secondary preven-
tion must aim to reduce their complications, intensifying 
previous measures and initiating the appropriate drug 
therapy. Particular aspects of the pharmacological ap-
proach are discussed below.
 Theoretically, any kind of intervention aiming to re-
duce vascular calcification should curtail the influence of 
factors that promote calcifications and/or augment the 
effects of factors that may inhibit calcifications  [37] . Most 
strategies to reduce vascular calcifications have focused 
on the most common modifiable risk factors such as hy-
perphosphataemia, hypercalcaemia, the CaxP product, 
hyperparathyroidism, smoking, dyslipidaemia or hyper-
tension ( table 2 ).
Table 2.  Strategies to reduce vascular calcification
Balanced diet, with low salt and saturated fats intake
Regular physical exercise
Smoking abstinence
Low alcohol intake
Control of serum phosphorus and calcium levels
Use of physiologic doses of vitamin D
Treatment of secondary hyperparathyroidism
Lipid-lowering therapy with statins
Treatment of hypertension
Rigorous control of diabetes mellitus
Caution with acenocumarol or warfarin treatments
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 Control of Hyperphosphataemia, Hypercalcaemia and 
CaxP Product 
 Disturbances in serum phosphorus, calcium and the 
calcium-phosphorus product are frequently seen in CKD 
patients and are implicated in the promotion of vascular 
calcification as well as in an increased death risk  [37] . Be-
cause dietary restriction of phosphorus and intermittent 
dialysis are not usually effective in controlling serum 
phosphorus, most patients with CKD stage 5 show a high 
prevalence of hyperphosphataemia with its known impli-
cations in the pathogenesis of secondary hyperparathy-
roidism, cardiovascular alterations and mortality. As 
mentioned before, in vivo and in vitro studies shed light 
on the role of phosphorus as a promoter of vascular cal-
cification, demonstrating that the control of phosphorus 
should be a priority in clinical practice.
 Calcium-based phosphate binders such as calcium ac-
etate and calcium carbonate have replaced aluminium 
hydroxide as the most widely prescribed phosphate bind-
ers. The possible negative role of calcium overload from 
these binders on the progression of vascular calcifica-
tions has led to the progressive but not total reduction of 
calcium- and aluminium-based phosphate binders in fa-
vour of new calcium- and aluminium-free phosphate 
binders (sevelamer hydrochloride, sevelamer carbonate 
and lanthanum carbonate). These new compounds have 
been shown to have reduced hypercalcaemic adverse 
events in comparison to calcium-based phosphate bind-
ers  [38] .
 An experimental study demonstrated that treatment 
with sevelamer in rats decreased renal calcification com-
pared to rats that received calcium carbonate and un-
treated rats  [39] . In addition, a clinical trial showed that 
sevelamer reduced the progression of both coronary and 
aortic calcifications compared to calcium carbonate  [40] . 
However, the mechanism of the beneficial effect of 
sevelamer on the progression of calcification is still not 
fully understood. One possible mechanism is based on 
the reduction of the calcium load; however, reduced vas-
cular calcification may also result from reductions in to-
tal and LDL cholesterol, which occur during treatment 
with sevelamer  [38] . In fact, two recent studies have shed 
doubts on the role of phosphate binders in the progres-
sion of calcification  [41, 42] .
 Control of Secondary Hyperparathyroidism:
Vitamin D and Calcimimetics 
 The use of vitamin D metabolites is a challenging sub-
ject that still remains controversial. The current treat-
ment of secondary hyperparathyroidism in dialysis pa-
tients includes suppression of PTH with supraphysiolog-
ic doses of vitamin D or its analogues. Although it is 
widely known that a high dosage of vitamin D metabo-
lites favours the onset and progression of vascular calci-
fications, several studies have paradoxically demonstrat-
ed a long-term beneficial effect of vitamin D on vascular 
calcifications. Low vitamin D status is associated with a 
higher prevalence of vascular calcifications, bone and 
mineral disturbances, susceptibility to some infections, 
higher risk of autoimmune diseases, some malignancies 
and many other complications  [43] .
 Observational studies in patients on HD and in the 
general population have also demonstrated a lower mor-
bidity and a cardiovascular survival advantage in pa-
tients who are treated with vitamin D receptor activators 
 [44, 45] .
 A major breakthrough in the management of calcium 
and phosphate metabolism in dialysis patients was 
achieved recently with the introduction of calcimimetics. 
These compounds were the first agents introduced to 
lower PTH with advantageous effects on serum calcium 
and phosphate. It has been demonstrated experimentally 
that the calcimimetic R568 reduces aortic calcifications 
and mortality in rats in which aortic calcifications were 
induced using a high dose of calcitriol  [46] . Moreover, 
another experimental study showed that calcimimetics 
may even favour the regression of vascular calcification 
 [47] .
 Control of Dyslipidemia 
 Dyslipidemia, particularly increased LDL cholesterol, 
has been implicated in the progression of vascular calci-
fications. In addition, in the general population, the ben-
eficial effect of lowering LDL cholesterol levels on the 
progression of calcification has been reported by several 
groups  [48, 49] . As mentioned previously, patients who 
were treated with sevelamer showed a significant de-
crease in LDL cholesterol levels  [40] , which may explain 
the beneficial effects in the progression of cardiovascular 
calcification. It is known that the rapid progression of 
coronary arterial calcification in HD patients is associ-
ated with higher triglycerides and lower HDL cholesterol 
levels  [50] .
 Control of Blood Pressure 
 Hypertension is a modifiable risk factor for vascular 
calcifications in both the general population and CKD 
patients. Several studies in patients with end-stage renal 
disease and essential hypertension have shown that arte-
rial stiffening is an independent predictor of mortality. 
D
ow
nl
oa
de
d 
by
: 
15
6.
35
.1
92
.4
 - 
3/
16
/2
01
5 
1:
14
:3
6 
PM
 Vascular Calcification in Chronic Kidney 
Disease 
Med Princ Pract 2011;20:203–212 207
As arteries become stiffer, the pulse wave velocity in-
creases and it is responsible for a rapid return of wave 
 reflections from the periphery to the ascending aorta 
during systole, which causes an abnormal rise of aortic 
systolic blood pressure with decreased diastolic blood 
pressure and high pulse pressure. Increased wave reflec-
tions and high pulse pressure are independent risk factors 
for mortality in end-stage renal disease patients  [51] .
 Diabetes 
 Diabetes is a disease that is known to be complicated 
by heterogeneous metabolic risk factors, such as hyper-
glycemia, dyslipidemia, insulin resistance, glycation, ox-
idative and carbonic stress, and tissue hypoxia. In the 
non-uremic population, vascular calcification occurs 
more frequently in diabetics. In CKD patients, vascular 
calcification in diabetics has been reported to be more 
prevalent and more advanced than in non-diabetics  [52] . 
Several studies emphasize the importance of glycaemic 
control in the prevention of the development and pro-
gression of vascular calcification in diabetic CKD pa-
tients  [53] .
 Factors That Decrease Vascular Calcification 
 Although vascular calcification is very common in pa-
tients with CKD, it is absent in a non-negligible percent-
age of patients (close to 20%) despite a similar exposure 
to the known factors that promote calcification  [54] . As 
mentioned before, inhibitors of the precipitation of cal-
cium and phosphate must be playing a major role in pre-
venting extra-osseous calcification. Unfortunately, the 
therapeutic potential of these inhibitors of calcification 
has not been explored in clinical trials. Because MGP re-
quires vitamin K for   -carboxylation, an acquired vita-
min K deficiency by the use of warfarin or acenocumarol 
may predispose towards vascular calcification  [55] .
 Clinical and experimental studies have consistently 
established a positive association between arterial calci-
fication and bone resorption  [56, 57] . Consequently, it 
can be hypothesized that treatment strategies that simul-
taneously reduce bone resorption and increase bone min-
eralization may decrease the risk of vascular calcifica-
tions.
 Bisphosphonates, used as standard therapy for osteo-
porosis, inhibit the experimentally induced vascular cal-
cification, offering perspectives for the treatment of vas-
cular calcification. The exact mechanism by which 
bisphosphonates inhibit arterial calcification is not en-
tirely understood. One possibility is an indirect effect 
through inhibition of bone resorption, which would re-
duce the efflux of calcium and phosphate out of the bone, 
resulting in a decreased performance of the substrates re-
quired to form hydroxyapatite in the arterial wall  [58] .
 Bisphosphonates have been demonstrated to reduce 
vascular calcification in experimental models  [59] , but 
also in CKD in a reduced group of HD patients  [60] . Nev-
ertheless, the use of bisphosphonates, particularly in 
CKD patients with underlying renal osteodystrophy, 
should be carefully considered as they are still in the re-
search phase  [58] . It has been recently described that in 
uremic rats treated with bisphosphonates, there was a 
strong correlation between inhibition of aortic calcifica-
tion and bone mineralization, suggesting that bisphos-
phonates may not be able to prevent vascular calcification 
without inhibiting bone formation  [61] .
 Even though new strategies may improve the manage-
ment of vascular diseases and, more specifically, may 
have a positive impact on the high prevalence of vascular 
calcifications, the more effective approach is still that in-
volving the best possible control of mineral and bone me-
tabolism and inflammatory parameters  [11] .
 We need more experimental, epidemiological and 
randomised clinical studies designed to ascertain the ef-
fects of the newly available bone-vascular active drugs on 
the bone and cardiovascular systems.
 Molecular Aspects Related to Vascular Calcification 
 Until recent years, vascular calcification was consid-
ered the result of a simple precipitation of the circulating 
calcium and phosphate. However, the mechanisms by 
which the process of vascular calcification is produced 
are complex; it does not consist of a simple precipitation 
of calcium and phosphate, it involves active and modifi-
able processes that will be discussed later in this review. 
The final result is the formation of bone structures inside 
the artery wall  [62, 63] . This regulated process involves 
several changes, such as the decrease in vascular calcifi-
cation inhibitors  [64] , increase in vascular calcification 
promoters, formation of calcification vesicles  [65] , and, as 
a result, the induction of a cellular phenotypic change: 
from vascular smooth muscle cells (VSMCs) to bone-like 
cells  [66, 67] . Interestingly enough and in line with sev-
eral epidemiological studies, the increase in bone-like 
cells in the vessels has been reported to be associated to a 
decrease in bone mass and mineralization  [11, 35, 68] .
 Thanks to the advances in molecular biology, a great 
number of mechanisms have been extensively investigat-
ed, and several inhibitors and promoters of vascular cal-
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cification have been described ( fig. 1 ). Among the latter, 
phosphorus and calcium play a relevant role. In humans 
and other mammals, serum concentrations of calcium 
and phosphate exceed the calcium-phosphate solubility 
product; thus, the likelihood of precipitation is high. Nev-
ertheless, in both young and adult populations, intra-ves-
sel precipitation is uncommon, clearly stressing the im-
portant role played by the vascular calcification inhibi-
tors in preventing calcium/phosphate precipitation and 
deposition.
 Promoters of Vascular Calcification: Phosphorus, 
Bone Morphogenetic Protein-Msx-2-Wnt Axis, 
Inflammation and Oxidative Stress 
 High serum phosphorus is the most important ure-
mia-related, non-traditional risk factor associated with 
vascular calcification in CKD patients and the general 
population  [17] . It is well known that high serum phos-
phorus levels stimulate parathyroid activity, decreasing 
the levels of calcium-sensing receptor and vitamin D re-
ceptor; it also lowers the activity of 1-  -hydroxylase, con-
sequently decreasing serum calcitriol levels.
 In addition, phosphorus is also capable of acting as a 
secondary intracellular messenger, activating several 
molecular pathways related to bone formation. It reaches 
the intracellular space via a specific Na-dependent chan-
nel called Pit-1 and exerts some interesting actions; in 
fact, the blockade of Pit-1 prevents vascular calcification 
 [69] .
 In vitro experiments have demonstrated that elevated 
intracellular phosphate levels may directly increase an 
important bone-specific transcription factor core-bind-
ing factor   (Cbfa-1), resulting in the activation of sev-
eral osteogenic pathways in the VSMCs, which leads to 
phenotypic changes of VSMCs into bone-like cells  [70, 
71] .
 Focusing on the downstream actions of Cbfa-1, it pro-
motes the expression of osteocalcin and alkaline phos-
phatase in the vasculature. In addition, one of the most 
important families of proteins involved in mineralization 
and vascular calcification, the bone morphogenetic pro-
teins (BMPs) are activated by Cbfa-1. The BMP family, 
especially the 2 and 4 members, have been described as 
potent promoters of vascular calcification, as they can re-
Collagen I
Fibronectin
Collagen IV
MSX-2 PTH 7-84
PTHrP
TNF-
Oncostatin
Osteocalcin
CBfa1
ALP
Ca
Osteoprotegerin
Osteopontin
Pyrophosphate
Vit D3
Klotho–/–
LDLox
BMP2
BMP7
PTH 1-34
MGP
Fetuin
Leptin Pi
Promoters of vascular
calcification
Wnt pathway
Inhibitors of vascular
calcification
VSMC ‘Osteoblast-like’
‘Vascular osteoblasts’
 Fig. 1. Promoters and inhibitors of vascu-
lar calcification. 
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cruit other bone-related players such as Msx-2 and Wnt-
related proteins  [72–74] . Inflammation is also an impor-
tant factor involved in the pathogenesis of vascular calci-
fication development  [75] .
 Oxidative stress has also been related to vascular cal-
cification. VSMCs cultured with H 2 O 2 developed calcifi-
cation via stimulation of Cbfa-1  [76] . In addition, in vivo 
studies have shown that some antioxidants can prevent 
vascular calcification  [77] . In agreement with these ex-
perimental analyses, clinical studies have shown that se-
rum levels of oxidized LDL, advanced oxidation protein 
products and urine levels of F-2 isosprostanes (biomark-
ers of oxidative stress) may all be considered as risk fac-
tors for vascular and valvular calcification  [25, 78] .
 Inhibitors of Vascular Calcification: Pyrophosphates, 
Fetuin A and Osteoprotegerin 
 Pyrophosphates (PPi) are located in the vascular ma-
trix and they are supposed to preserve the aortic VSMC 
phenotype, thanks to the inhibition of calcium carbonate 
formation, hence inhibiting calcium phosphate crystal 
formation; PPi inhibits the change of VSMCs into bone-
like cells  [79, 80] .
 In serum, the most abundant inhibitors of vascular 
calcification are fetuin-A (  2-Heremans-Schmid glyco-
protein), osteoprotegerin (OPG) and matrix-gla protein. 
Fetuin-A is a known inhibitor of osteogenesis  [81] , ca-
pable of inhibiting vascular calcification  [82] . Fetuin-A 
knockout mice spontaneously develop widespread soft 
tissue calcification, including significant myocardial cal-
cification, findings associated to the upregulation of the 
profibrotic factor TGF-   [83] .
 OPG inhibits osteoclast differentiation, modulating 
bone resorption through its action as a decoy receptor of 
RANKL. OPG-null mice develop early-onset osteoporo-
sis and severe medial layer calcification  [84] , suggesting 
that OPG acts as an inhibitor of in vivo vascular calcifica-
tion. OPG was shown to inhibit ALP activity in aortic 
tissue and prevent the progression of medial layer vascu-
lar calcification  [85] . The importance of the OPG/RANKL 
axis in vascular calcification has been recently shown; the 
increase in vascular calcium content was parallel to an 
increase in the RANKL and BMP4 expression  [86] .
 Other Players 
 Klotho, a co-receptor of fibroblast growth factor 23 
(FGF-23), among other functions, has a phosphaturic 
function  [87, 88] . The knockout mice for the Klotho gene 
showed accelerating aging with widespread ectopic calci-
fication, including vascular calcifications. The mecha-
nisms by which fibroblast growth factor 23/Klotho affect 
vascular calcification may involve phosphate excretion as 
well as vitamin D and PTH leading to vascular calcifica-
tion and bone loss  [89–92] .
 Advanced glycation end-products (AGEs) are chemical 
modifications of proteins and lipids that become non-en-
zymatically glycated after contact with carbohydrates 
 [93] . The generation of AGEs is a continous in vivo process 
and their accumulation increases with aging and diseases, 
specially diabetes  [94] . AGEs accumulate in the vessel wall 
and contribute to the development of atherosclerosis 
through the formation of cross-links between molecules 
in the basement membrane of the extracellular matrix, 
involving different cell-surface receptors, especially 
RAGE  [95] . Furthermore, recent studies have shown a cor-
relation between the accumulation of AGEs in bone and 
increased fracture risk, even with normal bone mineral 
density  [96–98] . AGEs may induce abnormal cross-links 
in the collagen proteins causing bone fragility  [99, 100] . 
Furthermore, they may decrease osteoblast function and 
increase osteoclast activity, alter the function of the osteo-
blasts and increase the activity of the osteoclasts  [101] .
 In summary, vascular calcification, an established 
highly prevalent finding of CKD, known since the be-
ginning of renal replacement therapy, has recently re-
emerged as a key complication of CKD, and great efforts 
are currently underway to clarify the morphological, 
functional and molecular aspects of this disorder.
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